专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08216172B2 Method of performing hemofiltration 有权
标题翻译：进行血液滤过的方法
公开(公告)号：US08216172B2
公开(公告)日：2012-07-10
申请号：US13287683
申请日：2011-11-02
申请人： Peter C. Chang , Jean-Michel Lannoy
发明人： Peter C. Chang , Jean-Michel Lannoy
IPC分类号： A61M1/34 , A61K33/06 , A61K33/20 , A61K33/42 , A61K33/00 , A01N1/02
CPC分类号： A61M1/3672 , A61K31/19 , A61K33/06 , A61K33/14 , A61K33/42 , A61K45/06 , A61M1/3437 , A61M1/3458 , A61M1/3675 , Y10S514/822 , A61K2300/00
摘要： A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolytes but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.
摘要翻译：提供了用于体外血液处理的多部分替代输注液及其使用方法。通常，多部分取代流体包括由电解质组成但不含二价阳离子的第一溶液和包含二价阳离子的第二溶液。另一个实施方案包括含有匹配的柠檬酸盐/柠檬酸抗凝剂的第三溶液。所描述的使用多部分替代输注液的方法显着降低与各种体外血液治疗相关的风险。

2. 发明授权

US08163749B2 Six-membered heterocycles useful as serine protease inhibitors 有权
标题翻译：用作丝氨酸蛋白酶抑制剂的六元杂环
公开(公告)号：US08163749B2
公开(公告)日：2012-04-24
申请号：US12097080
申请日：2006-12-13
申请人： James R. Corte
发明人： James R. Corte
IPC分类号： A01N43/58 , A61K31/50 , A61K31/44 , A61K31/13 , C07D221/18 , C07D421/00
CPC分类号： C07D213/40 , C07D213/54 , C07D213/63 , C07D213/64 , C07D213/73 , C07D213/89 , C07D239/26 , C07D401/04 , Y10S514/822
摘要： The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, R3 and R11 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
摘要翻译：本发明提供式（I）化合物或其立体异构体，互变异构体，药学上可接受的盐或溶剂合物形式，其中变量A，B，R 3和R 11如本文所定义。式（I）的化合物可用作凝血级联和/或接触激活系统的丝氨酸蛋白酶的选择性抑制剂; 例如凝血酶，因子Xa，因子XIa，因子IXa，因子VIIa和/或血浆激肽释放酶。特别地，它涉及作为选择性因子XIa抑制剂或fXIa和血浆激肽释放酶的双重抑制剂的化合物。本发明还涉及包含这些化合物的药物组合物和使用其制备血栓栓塞和/或炎症性疾病的方法。

3. 发明申请

US20100301268A1 MULTI-PART SUBSTITUTION INFUSION FLUIDS AND MATCHING ANTICOAGULANTS 有权
标题翻译：多部分替代输注液和匹配抗凝剂
公开(公告)号：US20100301268A1
公开(公告)日：2010-12-02
申请号：US12831811
申请日：2010-07-07
申请人： Peter C. Chang , Jean-Michel Lannoy
发明人： Peter C. Chang , Jean-Michel Lannoy
IPC分类号： C09K3/00
CPC分类号： A61M1/3672 , A61K31/19 , A61K33/06 , A61K33/14 , A61K33/42 , A61K45/06 , A61M1/3437 , A61M1/3458 , A61M1/3675 , Y10S514/822 , A61K2300/00
摘要： A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolites but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.
摘要翻译：提供了用于体外血液处理的多部分替代输注液及其使用方法。通常，多部分取代流体包括由电石而不含二价阳离子组成的第一溶液和包含二价阳离子的第二溶液。另一个实施方案包括含有匹配的柠檬酸盐/柠檬酸抗凝剂的第三溶液。所描述的使用多部分替代输注液的方法显着降低与各种体外血液治疗相关的风险。

4. 发明授权

US07279183B2 Method of reducing thrombosis and complications after arterial angioplasty using stent coated with magnesium-based compound 有权
标题翻译：使用含有镁基化合物的支架进行动脉血管成形术后减少血栓形成和并发症的方法
公开(公告)号：US07279183B2
公开(公告)日：2007-10-09
申请号：US10746048
申请日：2003-12-24
申请人： Sanjay Kaul , Prediman K. Shah
发明人： Sanjay Kaul , Prediman K. Shah
IPC分类号： A61K33/06 , A61K33/08 , A61K33/12 , A61K33/14 , A61K33/42 , A61P9/14 , A61P43/00 , A61P41/00 , A61F2/06
CPC分类号： A61L31/16 , A61K31/727 , A61K33/06 , A61K33/08 , A61L2300/102 , A61L2300/42 , A61L2300/606 , Y10S514/822 , Y10S623/921 , A61K2300/00
摘要： Treatment with magnesium produces a inhibition of acute stent thrombosis under high-shear flow conditions without any hemostatic or significant hemodynamic complications.
摘要翻译：用镁治疗可在高剪切流动条件下产生急性支架血栓形成的抑制，无任何止血或显着的血液动力学并发症。

5. 发明申请

US20070134348A1 MULTI-PART SUBSTITUTION INFUSION FLUIDS AND MATCHING ANTICOAGULANTS 有权
标题翻译：多部分替代输注液和匹配抗凝剂
公开(公告)号：US20070134348A1
公开(公告)日：2007-06-14
申请号：US11678525
申请日：2007-02-23
申请人： Peter Chang , Jean-Michel Lannoy
发明人： Peter Chang , Jean-Michel Lannoy
IPC分类号： A61K33/42 , A61K33/14 , A61K31/19
CPC分类号： A61M1/3672 , A61K31/19 , A61K33/06 , A61K33/14 , A61K33/42 , A61K45/06 , A61M1/3437 , A61M1/3458 , A61M1/3675 , Y10S514/822 , A61K2300/00
摘要： A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolites but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.
摘要翻译：提供了用于体外血液处理的多部分替代输注液及其使用方法。通常，多部分取代流体包括由电石而不含二价阳离子组成的第一溶液和包含二价阳离子的第二溶液。另一个实施方案包括含有匹配的柠檬酸盐/柠檬酸抗凝剂的第三溶液。所描述的使用多部分替代输注液的方法显着降低与各种体外血液治疗相关的风险。

6. 发明申请

US20060183729A1 Vanadium compounds as anti-angiogenic agents 审中-公开
标题翻译：钒化合物作为抗血管生成剂
公开(公告)号：US20060183729A1
公开(公告)日：2006-08-17
申请号：US11203521
申请日：2005-08-12
申请人： Fatih Uckun
发明人： Fatih Uckun
IPC分类号： A61K31/555 , A61K31/28
CPC分类号： A61K31/28 , A61K31/555 , A61K33/24 , Y10S514/822 , Y10S514/824 , Y10S514/863 , Y10S514/866 , Y10S514/883 , Y10S514/908 , Y10S514/912 , Y10S514/954
摘要： Vanadium compounds for inhibiting angiogenesis useful for treating or preventing diabetic retinopathy, hemangiomas, cancers with abnormal blood vessel supply, restenosis following vascular injury, and the like.
摘要翻译：用于抑制血管生成的钒化合物可用于治疗或预防糖尿病性视网膜病变，血管瘤，血管供应异常的癌症，血管损伤后的再狭窄等。

7. 发明申请

US20050255108A1 Co-administration of a thrombolytic and an-anti-CD18 antibody in stroke 有权
标题翻译：溶栓和抗CD18抗体在中风中共同给药
公开(公告)号：US20050255108A1
公开(公告)日：2005-11-17
申请号：US11025712
申请日：2004-12-28
申请人： Martin Bednar , Cordell Gross , Linda Gross , G. Thomas
发明人： Martin Bednar , Cordell Gross , Linda Gross , G. Thomas
IPC分类号： A61K38/00 , A61K38/18 , A61K38/49 , A61K39/395 , C07K16/28
CPC分类号： C07K16/2845 , A61K38/49 , A61K39/3955 , A61K2039/505 , C07K16/2821 , C07K2317/24 , C07K2317/54 , C07K2317/76 , Y10S514/822 , A61K2300/00
摘要： A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.
摘要翻译：描述了一种通过增加脑血流量和/或降低梗死面积来改善哺乳动物局部缺血性卒中临床结果的方法，其涉及在没有移除动脉的情况下向哺乳动物施用有效量的抗CD18抗体梗阻。

8. 发明申请

US20040247642A1 Instrument coated with magnesium-based compound for reducing thrombosis 有权
标题翻译：仪器涂有镁基化合物以减少血栓形成
公开(公告)号：US20040247642A1
公开(公告)日：2004-12-09
申请号：US10746958
申请日：2003-12-24
申请人： Cedars-Sinai Medical Center
发明人： Sanjay Kaul , Prediman K. Shah
IPC分类号： A61K031/727 , A61K033/06 , A61K033/14
CPC分类号： A61L31/16 , A61K31/727 , A61K33/06 , A61K33/08 , A61L2300/102 , A61L2300/42 , A61L2300/606 , Y10S514/822 , Y10S623/921 , A61K2300/00
摘要： Treatment with magnesium produces a inhibition of acute stent thrombosis under high-shear flow conditions without any hemostatic or significant hemodynamic complications.
摘要翻译：用镁治疗可在高剪切流动条件下产生急性支架血栓形成的抑制，无任何止血或显着的血液动力学并发症。

9. 发明授权

US06825168B2 Antithrombin protein and DNA sequences from black fly 失效
标题翻译：来自黑蝇的抗凝血酶蛋白和DNA序列
公开(公告)号：US06825168B2
公开(公告)日：2004-11-30
申请号：US10196117
申请日：2002-07-16
申请人： Mary S. Cupp , Eddie W. Cupp
发明人： Mary S. Cupp , Eddie W. Cupp
IPC分类号： A61K3816
CPC分类号： C07K14/43577 , A61K38/00 , Y10S514/822
摘要： The invention is drawn to anti-thrombin proteins from the salivary glands of the species, Simulium. Methods for recombinant production of the protein as well as biomedical uses are provided.
摘要翻译：本发明涉及来自该物种唾液腺的抗凝血酶蛋白质。提供了重组生产蛋白质以及生物医学用途的方法。

10. 发明授权

US06808706B1 Method for keeping the quality of aqueous parenteral solution of thrombomodulin in storage and distribution 失效
标题翻译：保持血栓调节素水溶液的质量的方法
公开(公告)号：US06808706B1
公开(公告)日：2004-10-26
申请号：US09509994
申请日：2000-05-08
申请人： Masaki Yui , Akira Yokozawa , Tomoyo Murata , Kazuhisa Tsuruta , Hirotomo Shimizu
发明人： Masaki Yui , Akira Yokozawa , Tomoyo Murata , Kazuhisa Tsuruta , Hirotomo Shimizu
IPC分类号： C12N900
CPC分类号： A61K9/0019 , A61K38/00 , A61K47/02 , A61K47/12 , A61K47/26 , A61K47/44 , C07K14/7455 , Y10S514/822
摘要： A method for keeping the quality of an aqueous parenteral solution of thrombomodulin which is not in a frozen or freeze-dried state but in a liquid form in storage and distribution, characterized in that the aqueous thrombomodulin solution containing an effective amount of soluble thrombomodulin and a buffer component exhibiting a buffering activity in a pH range of 5 to 7.0 has a pH of 5 to 7.0 and that (a) the aqueous thrombomodulin solution further contains a surfactant and is in a state aseptically filled into a case or (b) the aqueous thrombomodulin solution is the form of a prefilled syringe preparation produced by aseptically filling the thrombomodulin solution into a syringe substantially without any empty space. This method provides for the storage and distribution of an aqueous parenteral solution of thrombomodulin in a liquid state for a prolonged period and makes it possible to provide an aqueous parenteral solution which is excellent in long-term stability and shaking stability and can save the trouble of dissolving in use.
摘要翻译：一种保持不是冷冻或冷冻干燥状态而是液体形式的血栓调节蛋白的水性肠胃外溶液的储存和分配的质量的方法，其特征在于含有有效量的可溶性血栓调节蛋白和在5〜7.0的pH范围内表现出缓冲活性的缓冲成分的pH为5〜7.0，（a）血栓调节素水溶液还含有表面活性剂，处于无菌填充状态的状态，或（b）血栓调节蛋白溶液是通过将基本上没有任何空白空间无菌地将血栓调节蛋白溶液注入注射器而制备的预充式注射器制剂的形式。该方法提供长时间稳定的液体状态的血栓调节蛋白的肠胃外水溶液的储存和分配，能够提供长期稳定性和摇晃稳定性优异的水性肠胃外溶液，并且可以节省溶于使用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式